Thanks very much. That definitely put a lot into perspective.As...

First 3 Last

Share
Profile

Follow
Micko13

258 Posts.

24

21/08/20

00:25

Post #: 46704047
Share

Originally posted by tinhat: ↑

No worries. i'm going to explain it simply because my understanding is rather simple. Others can correct any errors or omissions.

Kazia trades on NASDAQ under the ticker KZIA. The shares traded on NASDAQ are depository notes. There are one NASDAQ listed depistory notes to every ten Kazia ordinary share (as listed on the ASX).

The NASDAQ traded depository notes represent shares held by Bank of New York Mellon Corporation (BNYMC). So the only way shares can be traded on NASDAQ (as depository notes) is as shares held by BNYMC.

Kazia, as a small cap biotech, has had to raise capital over the years, including earlier this year. The capital raisings have occurred through issuing new shares on the ASX. There have not been any shares issued through capital raisings on NASDAQ. The only shares that make it onto NASDAQ are the shares held by BNYMC. So, as things go, as more shares get issued and listed on the ASX through the necessary capital raising that a small cap company like KZA has had to make, they have slowly drifted onto the NASDAQ.

This drift has come about through what is termed in formal economics as an "arbitrage" trade. The net demand/supply for Kazia shares on NASDAQ has been generally been greater than relative demand/supply on the ASX because the supply of new shares, issued through capital raises, can only become liquid on the ASX, thus supply comes onto the ASX and flows onto NASDAQ through relatively higher demand to supply than on the ASX via BNYMC increasing its holding in KZA shares and making them available as depository notes to be traded on the NASDAQ.

Check the recent announcements, but I think BNYMC is now holding something like about 31% of Kazia ordinary share stock. These are the shares available for trade as 10:1 depistory notes on NASDAQ.

Expand

Thanks very much. That definitely put a lot into perspective.

As it stands, do holders feel there's too much liquidity with this Small Cap or not enough between markets, to help move prices?
As I read earlier (can't recall poster) KZAs portfolio looks a hell of a lot better than other Biotechs but seems to be fighting to maintain strength. Even now, with good news, I wouldn't be surprised if this pulled back. Seems to be it's Trend, Covid aside. Your thoughts.

Cheers Micko

KZA Price at posting: $1.12 Sentiment: None Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 46, 2024

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

First 3 Last

Add KZA (ASX) to my watchlist

Thanks very much. That definitely put a lot into perspective.As...

Top Stories

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Banshee's historic trenches prove rich in antimony and gold for GDM

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Cyclone signs MOU with Vale for development of Iron Bear play

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Featured News